H3-DYNAMICS
23.11.2022 07:01:43 CET | Business Wire | Press release
The future of hydrogen aviation powered by H3 Dynamics’ distributed hydrogen propulsion nacelles has taken flight for the very first time in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121006001/en/
H3 Dynamics distributed hydrogen electric nacelles proven on first flight (Photo: Business Wire)
Following the announcement of its hydrogen aviation concept back in 2018, H3 Dynamics managed to become a topic at an Oval Office press conference on the very next day, and started what is now a global hydrogen aviation movement.
In November 2021, H3 Dynamics completed its first working hydrogen propulsion nacelle prototype. In July 2022, the first distributed pod system took to the skies on a scaled-down aircraft at “Hub Drones - Systematic” airfield near Paris. The hydrogen flight received clearance from the French civil air authorities (DGAC).
H3 Dynamics’ self-contained nacelle approach addresses technical, safety and cost challenges hydrogen aircraft developers could face at some point in the future. It achieves this by placing hydrogen and smaller fuel cells across a series of collaborative propulsion nacelles under the wings. A new 2022 study forecasts the global thrust nacelle market to reach $7 Billion by 2030 highlights H3 Dynamics’ hydrogen solution as a key new opportunity in the sector.
Other, higher-visibility hydrogen aircraft proponents will fly larger size aircraft much sooner – but they will do so by converting existing aircraft using fuel cells sourced from the automotive world – and storing large amounts of gas or liquid hydrogen inside the main fuselage.
“Not only is safety our first priority, but we don’t want hydrogen competing for revenue-generating airfreight and passenger space,” said Taras Wankewycz, Founder/CEO of H3 Dynamics. Distributing small systems solves technical headaches, such as thermal management, and increases safety through multiple redundancy.
H3 Dynamics’ 25kg test aircraft is already a breakthrough - with an electric flight range of up to 900km on liquid hydrogen, or 350km with pressurized hydrogen. Its externalized nacelle design also frees up 30L of fuselage volume with no hydrogen nor any powertrain elements inside. H3 Dynamics’ hydrogen propulsion nacelles could potentially become a “snap-on” retrofit for battery-powered unmanned eVTOL or fixed wing cargo drones.
Preparing for the arrival of much longer duration unmanned hydrogen flights - H3 Dynamics started to work on airspace safety with world-leading air traffic control companies. It has been building experience with high-volume enterprise data services being deployed in smart cities such as Singapore, and gradually coupling these with drone-agnostic charging stations.
By starting at the lower-end boundary of regulatory and certification efforts, H3 Dynamics doesn’t need to wait until 2035 to begin its commercial journey. “We all need to learn today with small commercial applications and gradually increase aircraft size over time together with all stakeholders – most importantly, the regulators.”
Now H3 Dynamics is already preparing its next steps.
It is exploring liquid hydrogen integration as part of a joint-development with ISAE-SUPAERO in Toulouse launched in 2019. The objective is a historical and symbolic Atlantic crossing on hydrogen electric propulsion in the coming two years.
And with airfield experiments feeding its digital twin capability for hydrogen aircraft design, H3 Dynamics is now working on a next generation platform powered by 6 independent hydrogen-electric nacelle systems. The aircraft will feature fast-refueling and will be used as a test bed for H3 Dynamics hydrogen-electric propulsion technology moving forward.
About H3 Dynamics: www.h3dynamics.com
H3 Dynamics is on a long-term mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. While the commercial opportunities around passenger-scale hydrogen aviation continue to mature, the company is implementing an incremental product and services roadmap that solves safety, technical, regulatory challenges starting small and simple, adding scale and complexity over time. The company currently has 95 employees and serves clients globally from its 3 regional headquarters in Toulouse, Austin and Singapore. H3 Dynamics is member of the Alliance for Zero Emission Aviation under the European Commission, the Lufthansa Cleantech Hub, Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121006001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom